David Huang, MD, PhD, chief medical officer of Motif Bio, said, “We are delighted to have Stephanie join Motif.  Her strategic insights, experience and leadership in late-stage global clinical trials and the regulatory process, including post-marketing requirements, make her ideally suited for this position. I am very excited and am looking forward to working with Stephanie as we continue to progress iclaprim towards an approval.”